Division of Population Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Pallaitive and Advanced Illness Research Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
J Geriatr Oncol. 2018 Sep;9(5):459-463. doi: 10.1016/j.jgo.2018.03.004. Epub 2018 Mar 14.
To quantify the prevalence of self-reported major mobility disability (SR-MMD) and its association with mortality in a nationally-representative sample of cancer survivors.
This study included patients with a history of cancer who participated in the National Health and Nutrition Examination Survey 19992010. SR-MMD was defined as self-reported difficulty or inability to walk a quarter of a mile. Vital status through December 15, 2011 was ascertained from the United States National Center for Health Statistics. Multivariable-adjusted Cox regression models were used to quantify the hazard ratio (HR) and 95% confidence interval (CI) between SR-MMD and mortality.
The study included 1458 cancer survivors who averaged 67.1 years of age. At baseline, 201 (13.7%) participants had SR-MMD. During a median follow-up of 4.7 years, 434 (29.8%) participants died. SR-MMD was independently associated with a higher risk of all-cause mortality [HR: 2.15 (95% CI: 1.56-2.97); P < 0.001] and cancer-specific mortality [HR: 2.49 (95% CI: 1.53-4.07); P < 0.001]. The association between SR-MMD and all-cause mortality was not modified by age, sex, time since cancer diagnosis, body mass index, or comorbid health conditions.
SR-MMD is an easily ascertainable metric of physical function that is associated with a higher risk of mortality among cancer survivors. Integrating measures of physical function may help to guide clinical decision-making and improve long-term prognostication in this population. Interventions that prevent the development of SR-MDD, such as physical activity, should be evaluated in this population.
在具有全国代表性的癌症幸存者样本中,量化自我报告的主要移动障碍(SR-MMD)的流行率及其与死亡率的关系。
本研究纳入了参加 1999-2010 年全国健康和营养调查的有癌症病史的患者。SR-MMD 定义为自我报告行走四分之一英里有困难或无法行走。截至 2011 年 12 月 15 日的生存状态通过美国国家卫生统计中心确定。使用多变量调整的 Cox 回归模型来量化 SR-MMD 与死亡率之间的风险比(HR)和 95%置信区间(CI)。
本研究纳入了 1458 名平均年龄为 67.1 岁的癌症幸存者。基线时,201 名(13.7%)参与者有 SR-MMD。在平均 4.7 年的中位随访期间,434 名(29.8%)参与者死亡。SR-MMD 与全因死亡率[HR:2.15(95%CI:1.56-2.97);P<0.001]和癌症特异性死亡率[HR:2.49(95%CI:1.53-4.07);P<0.001]的风险增加独立相关。SR-MMD 与全因死亡率之间的关联不受年龄、性别、癌症诊断后时间、体重指数或合并健康状况的影响。
SR-MMD 是一种易于确定的身体功能指标,与癌症幸存者的死亡率升高相关。整合身体功能测量可能有助于指导该人群的临床决策并改善长期预后。应在该人群中评估预防 SR-MMD 发展的干预措施,例如身体活动。